This pilot early phase I trial studies the Automated Device for Asthma Monitoring and Management in monitoring adult patients with lung cancer who are undergoing radiation therapy. The Automated Device for Asthma Monitoring and Management may provide useful information to doctors to help monitor adult patients with lung cancer and diagnose certain conditions earlier than traditional means.
I. Determine compliance with the Automated Device for Asthma Monitoring and Management (ADAMM) device in patients receiving radiation therapy (RT) for lung cancer.
SECONDARY OBJECTIVES:
I. Evaluate feasibility of recruitment, acceptability of the ADAMM device, and compliance with electronic patient-reported outcomes (ePROs) in this patient population
Patients are capable of giving informed consent Patients are eligible to be treated with RT and plan to start treatment Patients have either metastatic or non-metastatic lung cancer as defined in history and physical Patients must be able to read or speak English Women of reproductive potential should have a negative serum or urine pregnancy test within one week prior to radiation planning CT scan
Exclusion Criteria:
Patients who cannot read or speak English Patients who are not candidates for RT treatment Women of childbearing potential who are pregnant or breastfeeding
